Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Alpha 1-blockers in hypertension.

¹Department of Clinical Pharmacology, Imperial College School of Medicine, St Mary's Hospital, London, UK.

Current Medical Research and Opinion

|September 24, 1999

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tissue Doppler echocardiography predicts long-term cardiovascular mortality: the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) legacy 20-year follow-up study.

Open heart·2025

Same author

ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data.

Journal of human hypertension·2013

Same author

Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach.

Diabetic medicine : a journal of the British Diabetic Association·2011

Same author

How common is true resistant hypertension?

Journal of human hypertension·2010

Same author

The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial.

International journal of clinical practice·2010

Same author

Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.

Heart (British Cardiac Society)·2007

Adding alpha 1-blockers to hypertension treatment enhances efficacy and tolerability. These drugs complement other antihypertensives, showing synergistic effects and potential metabolic benefits, improving patient compliance.

Area of Science:

Cardiology
Pharmacology

Background:

Hypertension is a complex disease with variable responses to single-drug treatments.
Combination therapy offers potential benefits like increased efficacy, better tolerability, and improved patient compliance.

Purpose of the Study:

To evaluate the benefits of co-administering alpha 1-blockers with other antihypertensive agents.
To explore the complementary mechanisms and synergistic effects of alpha 1-blockers in combination therapy.

Main Methods:

Review of existing data on alpha 1-blocker combination therapy.
Analysis of efficacy, tolerability, and metabolic effects in combined antihypertensive regimens.

Main Results:

Alpha 1-blockers demonstrate complementary mechanisms and enhanced efficacy when combined with other drug classes.

Related Experiment Videos

Synergistic effects observed with calcium channel blockers and ACE inhibitors.

Positive effects on lipid profiles and neutral to positive effects on glucose homeostasis noted.

Conclusions:

Alpha 1-blockers are well-tolerated in combination therapy, improving compliance.
Current data support the use of alpha 1-blockers as an adjunct in hypertension management.
Further research is needed on metabolic and end-organ effects of these combination regimens.